745550
Last Update Posted: 2012-04-20
Recruiting has ended
All Genders accepted | 18 Years + |
55 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis (CIMF) regardless of their JAK2 mutational status. The second portion of the study is a Phase 2 study to define the efficacy and safety profile of single agent SB1518 at the recommended dose in subjects with CIMF.
Eligibility
Relevant conditions:
Myelofibrosis
Myeloproliferative Disorders
Polycythemia Vera
Essential Thrombocythemia
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov